Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

Summary

Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.

Timeline

Start

2021-02

Primary completion

2021-08

Completion

2021-10

Outcome

Outcome not reported

Stopped (Enrollment): “Unable to recruit participants due to restrictive inclusion/exclusion criteria. Will update protocol with IRB \& begin anew after approval.”

Drugs

Indications